Teacher
Sandra Ferreira

Resume

Sandra Lourenço Ferreira. Concluiu o(a) Mestrado em Mestrado Integrado em Ciências Farmacêuticas em 2017/11 pelo(a) Instituto Superior de Ciências da Saúde Egas Moniz, Mestrado em Ciências Farmacêuticas em 2017 pelo(a) Instituto Universitário Egas Moniz, Doktor (PhD) em Ciências da Saúde (D) em 2025/11 pelo(a) Universidad de Alcala de Henares e Doktor (PhD) em Ciências da Saúde (D) em 2025/11 pelo(a) Universidade Lusófona de Humanidades e Tecnologias Centro de Investigação em Biociências e Tecnologias da Saúde. É Professor Auxiliar no(a) Universidade Lusófona de Humanidades e Tecnologias Escola de Ciências e Tecnologias da Saúde e Investigador no(a) Universidade Lusófona de Humanidades e Tecnologias Centro de Investigação em Biociências e Tecnologias da Saúde. Publicou 8 artigos em revistas especializadas. Organizou 6 evento(s). Participou em 22 evento(s). Participa e/ou participou como Bolseiro de Mestrado em 1 projeto(s) e Outra em 1 projeto(s). Atua na(s) área(s) de Ciências Médicas e da Saúde com ênfase em Medicina Básica com ênfase em Farmacologia e Farmácia, Ciências Exatas com ênfase em Ciências da Computação e da Informação com ênfase em Bioinformática, Ciências Exatas com ênfase em Química e Ciências Naturais com ênfase em Ciências Biológicas com ênfase em Biologia. No seu currículo Ciência Vitae os termos mais frequentes na contextualização da produção científica, tecnológica e artístico-cultural são: LOXL2; breast cancer; Cancer research; Breast cancer; inhibitors; natural compounds; bioinformatics; gene expression; immune infiltration; lysyl oxidase; pharmacological inhibitors; cell migration; dietary isothiocyanate; erucin; kidney cancer; tubulin; SDG 3 - Good Health and Well-being; 4-thiazolidone compounds; LOXL2 inhibitors; Cell invasion; Cell morphology; Triple negative breast cancer; Tubulin polymerisation; CIÊNCIAS FARMACÊUTICAS; CANCRO DA MAMA; ENZIMAS; PROTEÍNAS; PHARMACEUTICAL SCIENCES; BREAST CANCER; ENZYMES; PROTEINS; Produtos Naturais; Desenvolvimento de Fármacos; Estratégias de Formulação; Saúde Cutânea; Mecanismos de Doença; Nutrição e Metabolismo; .

Graus

• Mestrado
  Mestrado Integrado em Ciências Farmacêuticas
• Doktor (PhD)
  Ciências da Saúde (D)
• Outros
  Formação Avançada em Monitorização de Ensaios Clínicos
• Pós-Graduação
  YOUNG PHARMACISTS MANAGEMENT
• Outros
  Curso de formação Avançada, Fundamentos em cultura celular
• Outros
  Curso de formação Avançada, Manipulação e análise da expressão genética
• Pós-Graduação
  Data Science com Python
• Outros
  Bioinformática Molecular Curso Prático Online
• Outros
  Novel Challenges in Toxicology
• Outros
  Full Spectrum Flow Cytometry Course
• Outros
  “QuantStudio Real Time PCR SmartStart Orientation – Gene Expression (Relative Quantification) - Overview
• Mestrado
  Ciências Farmacêuticas

Publicações

Artigo em revista

• 2026-06, From virtual screening to cell phenotype: 4-thiazolidone scaffolds argeting LOXL2 in breast cancer, Chemical Biology and Drug Design
• 2023-09-05, P03-18: Lysyl oxidase like 2: an enzyme at the crossroad of Toxicology and Pharmacology, Toxicology Letters
• 2023-02, The Dietary Isothiocyanate Erucin Reduces Kidney Cell Motility by Disturbing Tubulin Polymerization, Molecular Nutrition and Food Research
• 2023, Evaluation of the Lysyl Oxidase-Like 2 (LOXL2) inhibitory activity of pimaranes and their glycosyl derivatives, Journal Biomedical and Biopharmaceutical Research
• 2023, Avaliação da atividade inibitória da proteína tipo Lisil oxidase 2 (LOXL2) de pimaranos e seus derivados glicosídicos
• 2022-06-21, Lysyl Oxidases Expression and Breast Cancer Progression, Frontiers in Pharmacology
• 2022-04-06, Polyphenols and Their Metabolites in Renal Diseases: An Overview, Foods
• 2021-02-19, LOXL2 Inhibitors and Breast Cancer Progression, Antioxidants

Artigo em jornal

• 2022-06-21, Lysyl Oxidases Expression and Breast Cancer Progression: A Bioinformatic Analysis, Front. Pharmacol

Entrada de enciclopédia

• LOXL2 Inhibitors and Breast Cancer Progression, Scholarly Community Encycolpedia
• LOXL2 Inhibitors and Breast Cancer Progression, Scholarly Community Encycolpedia

Resumo em conferência

• 2026-02-06, Targeting LOXL2 to Suppress Breast Cancer Invasion, VI Jornadas CBIOS
• 2026-02-06, Targeting LOXL2 to Suppress Breast Cancer Invasion, VI Jornadas CBIOS
• 2023-11-30, LusoModLox: in search of therapeutic lysyl oxidase inhibitors, CBIOS Conference
• 2023-09-06, P03-18: Lysyl oxidase like 2: an enzyme at the crossroad of Toxicology and Pharmacology
• 2023-09-06, Lysyl Oxidase Like 2: an enzyme at the crossroad of Toxicology and Pharmacology, 57th Congress of the European Societies of Toxicology (EUROTOX)
• 2023-02, A novel Lysyl Oxidase like 2 Inhibitor decreases breast cancer cells migration, 53rd Meeting of the Portuguese Society of Pharmacology
• 2023-02, A NOVEL LYSYL OXIDASE LIKE 2 INHIBITOR DECREASES BREAST CANCER CELLS MIGRATION, 53rd Meeting of the Portuguese Society of Pharmacology, 41st Meeting of Clinical Pharmacology and 22nd Meeting of Toxicology
• 2022-07-14, Lysyl oxidase like 2 as a therapeutic target for breast cancer: bioinformatics analysis and biochemical evaluation of 4-thiazolidinone derivatives, FEBS
• 2021-10-06, Bioinformatics analysis for Lysyl Oxidases as therapeutic targets for breast cancer

Poster em conferência

• 2026-02-06, Prolyl 4-hydroxylase subunit alpha 3 as a potential therapeutic target in triple-negative breast cancer, VI Jornadas CBIOS
• 2026-02-06, P4HA3 Is Upregulated in Breast Tumors and Cooperates with LOXL2 Inhibitors to Suppress TNBC Cell Viability, VI Jornadas CBIOS
• 2026-02-06, In silico pharmacokinetic and toxicological profiling of indoline-phenolic LOXL2 inhibitors, VI Jornadas CBIOS
• 2025-07, LOXL2 Inhibition: A New Strategy for Triple-Negative Breast Cancer, European Association for Cancer Research
• 2025-06-16, LOXL2 inhibition: a new strategy for triple-negative breast cancer, European Association for Cancer Research Congress 2025
• 2024-11-21, Potencial terapêutico de um novo inibidor LOXL2 no tratamento de cancro de mama triplo negativo, Congresso Nacional dos Farmacêuticos
• 2024-11, Potencial terapêutico de um novo inibidor LOXL2 no tratamento de cancro de mama triplo negativo., Congresso Nacional dos Farmacêuticos
• 2024-10-16, Exploring novel LOXL2 inhibitors: implications for breast cancer treatment, Champalimaud Research (CR) Symposium 2024
• 2024-10, Exploring novel LOXL2 inhibitors: Implications for breast cancer treatment., Champalimaud Research Symposium 2024
• 2024-09-24, Impacto de um potencial novo inibidor de LOXL2 em células de cancro de mama triplo negativo. , ENJIO - Liga Portuguesa Contra o Cancro
• 2024-09-24, Impacto de um potencial novo inibidor de LOXL2 em células de cancro de mama triplo negativo, 6.º Encontro Nacional de Jovens Investigadores em Oncologia
• 2024-07-03, Triazole derivative suppresses lysyl oxidase-like 2 activity, modifying breast cancer cell migration, Encontro Ciência 2024
• 2024-06, Triazole derivative suppresses lysyl oxidase-like 2 activity, modifying breast cancer cell migration., Encontro Ciência
• 2024-04-29, Targeting LOXL2 in Breast Cancer: novel triazole derivative inhibitor, 6th ASPIC International Congress
• 2024-04, Targeting LOXL2 in Breast Cancer: Novel triazole derivative inhibitor, 6th ASPIC International Congress
• 2023-11-25, Exploring the multifaceted potential of EPCU in targeting tumorigenesis and hormone regulation, 2nd Asian Student Council Symposium
• 2023-11-25, Exploring the Multifaceted Potential of EPCU in Targeting Tumorigenesis and Hormone Regulation, 2nd Asian Council Symposium
• 2022-07-09, Targeting lysyl oxidases for breast cancertherapy: bioinformatic analysis and evaluationof 4-thiazolidinone derivatives as LOXL2inhibitors, The Biochemistry Global Summit, 25th IUBMB Congress, 46th FEBS Congress, 15th PABMB Congress
• 2022-07, Targeting lysyl oxidases for breast cancertherapy: bioinformatic analysis and evaluationof 4-thiazolidinone derivatives as LOXL2inhibitors, The Biochemistry Global Summit, 25th IUBMB Congress, 46th FEBS Congress, 15th PABMB Congress
• 2021-11-18, Evaluation of the Lysyl Oxidase Like 2 (LOXL2) inhibitory activity of a natural pimarane and its sugar derivatives, II Bio.Natural-Bioactive Natural Products Research Meeting
• 2021-11, Evaluation of the Lysyl Oxidase Like 2 (LOXL2) inhibitory activity of a natural pimarane and its sugar derivatives, II Bio.Natural-Bioactive Natural Products Research Meeting
• 2021-10-07, Bioinformatics analysis for Lysyl Oxidases as therapeutic targets for breast cancer, Molecular Analysis for Precision Oncology Virtual Congress
• 2021-10, Lysyl Oxidases in the pathophysiology of breast cancer: a bioinformatics approach, 56º Congresso Anual da SBFIS Online
• 2021-10, Bioinformatics analysis for Lysyl Oxidases as therapeutic targets for breast cancer. Molecular, Analysis for Precision Oncology Virtual Congress 2021
• 2021-09-24, Lisil Oxidases como possíveis alvos terapêuticos para o cancro da mama: análise baseada na bioinformática, 3.º Encontro Nacional de Jovens Investigadores em Oncologia (ENJIO)
• 2021-09-24, Lisil Oxidases como possíveis alvos terapêuticos para o cancro da mama: análise baseada na bioinformática
• 2021-05-18, LOXL2 inhibitory activity of pimaranes from medicinal plants, conferência do Dia Internacional do Fascínio das Plantas
• 2021-05-18, LOXL2 inhibitory activity of pimaranes from medicinal plants, Dia Internacional do Fascínio das Plantas
• 2020-11-23, LOXL2 inhibitory activity of ultrasound aqueous extracts from medicinal plants, IV jornadas CBIOS